ASCO GU 2021 News : Episode 3

Video

ASCO GU 2021 News: Dr. Petros Grivas and Dr. Arlene Siefker-Radtke

Related Videos
Nancy U. Lin, MD, discusses the safety data from DESTINY-Breast12 with T-DXd for HER2+ advanced/metastatic breast cancer with or without brain metastases.
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
Daniel DeAngelo, MD, PhD
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Marc Machaalani, MD
Kimmie Ng, MD, MPH
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Kimmie Ng, MD, MPH
Ann H. Partridge, MD, MPH
Alicia Morgans, MD, MPH
Related Content
Dana-Farber Cancer Institute Faculty Among Highly Cited Researchers | Image Credit: © Cornflakesei - stock.adobe.com
November 21st 2024

Dana-Farber Cancer Institute Faculty Among World's Most Highly Cited Researchers for 2024

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

PD-L1, KIM-1 Expression in ccRCC | Image Credit: © Cornflakesei - stock.adobe.com
November 8th 2024

PD-L1, KIM-1 Expression Are Predictive of Outcomes With Adjuvant Nivolumab Alone, Plus Ipilimumab in ccRCC

Narjust Florez, MD
September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

Coleman Lindsley, MD, PhD
October 28th 2024

Rapid Blood Cancer Diagnostic Could Speed Decisions and Save Lives

Daniel DeAngelo MD, PhD, of Dana-Farber Cancer Institute
October 28th 2024

JAK Inhibitors Remain the Gold Standard in Myelofibrosis